

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPROVAL PACKAGE FOR:**

**APPLICATION NUMBER  
21-146**

**Microbiology Review(s)**

Natalia

JUN 16 2000

Review for Division of Cardio - Renal Drug Products, HFD-110  
Office of New Drug Chemistry, Microbiology Staff, HFD-805  
Microbiologists's Review No. 1

June 13, 2000

**MICROBIOLOGY REVIEWER:** Carol K. Vincent

A. 1. **NDA No.:** 21-146

**DRUG PRODUCT NAME:** Atropine Sulfate Injection

**APPLICANT:**

**DRUG PRODUCT MANUFACTURER:**

Abbott Laboratories  
D-389, Bldg. AP30  
200 Abbott Park Road  
Abbott Park, Illinois 60064-3537

Abbott Laboratories

2. **DOSAGE FORM AND ROUTE OF ADMINISTRATION:** Sterile liquid for injection.

3. **METHOD(S) OF STERILIZATION:** [ ]

4. **PHARMACOLOGICAL CATEGORY AND/OR PRINCIPAL INDICATION:**  
Treatment of sinus bradycardia and incomplete atrioventricular block.

5. **DRUG PRIORITY CLASSIFICATION:** 7 S

B. 1. **DOCUMENT DATE:** December 16, 1999

2. **DOCUMENT RECEIVED FOR REVIEW:** January 24, 2000

3. **COMIS USER FEE DUE DATE:** June 17, 2000

C. **REMARKS:** This NDA is one of a series of Abbott applications being submitted per MAPP 6020.2 [Applications for Parenteral Products in Plastic Immediate Containers, issued September 6, 1996] addressing the change from glass container to pre-filled 5- or 10- mL plastic syringe. Atropine Sulfate Injection was on the market in 1938, and was therefore "grandfathered" under the 1938 Food, Drug and Cosmetic Act. The currently marketed form is packaged in the Abboject® glass container.

D. **CONCLUSION and RECOMMENDATION:**

We recommend approval of NDA 21-146 from the microbiology prospective for sterilization process validation information for this drug product, Atropine Sulfate Injection. See "E. REVIEW NOTES:", below.

CC:

Orig. NDA 21-146

HFD-160/Consult/CKVincent [HFD-805]

HFD-110/FreddS/Jongedyk/Morgenstern

Drafted by: CKVincent/06-06-2000

Revised by: CKVincent/06-13-2000

[Signature]  
\_\_\_\_\_  
Carol K. Vincent

Review Microbiologist [HFD-805]

06-13-2000  
[Signature] 6/16/2000 [Signature]

Redacted 5

pages of trade

secret and/or

confidential

commercial

information